Articles published in Journal of Diabetes & Metabolism have been cited by esteemed scholars and scientists all around the world. Journal of Diabetes & Metabolism has got h-index 43, which means every article in Journal of Diabetes & Metabolism has got 43 average citations.
Following are the list of articles that have cited the articles published in Journal of Diabetes & Metabolism.
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
Year wise published articles |
107 | 59 | 61 | 45 | 23 |
Year wise citations received |
869 | 844 | 899 | 793 | 852 |
| Journal total citations count | 9622 |
| Journal impact factor | 12.50 |
| Journal 5 years impact factor | 18.23 |
| Journal cite score | 23.62 |
| Journal h-index | 43 |
| Journal h-index since 2018 | 28 |
| Journal Impact Factor 2020 formula |
| IF= Citations(y)/{Publications(y-1)+ Publications(y-2)} Y= Year |
| Journal 5-year Impact Factor 2020 formula |
| Citations(2016 + 2017 + 2018 + 2019 + 2020)/ {Published articles(2016 + 2017 + 2018 + 2019 + 2020)} |
| Journal citescore |
| Citescorey = Citationsy + Citationsy-1 + Citationsy-2 + Citations y-3 / Published articlesy + Published articlesy-1 + Published articlesy-2 + Published articles y-3 |
De Zeeuw D, Bekker P, Henkel E (2015) Inhibice chemokinového receptoru CCR2 snižuje u pacientů s diabetickou nefropatií reziduální albuminurii. |
|
Biswas SK, Bonecchi R (2016) Colonic Macrophages “Remote Control” Adipose Tissue Inflammation and Insulin Resistance. Cell Metabolism 24: 196-198. |
|
Zweemer AJ (2014) The ins and outs of ligand binding to CCR2 (Doctoral dissertation, Division of Medicinal Chemistry of the Leiden Academic Centre for Drug Research,, Faculty of Science, Leiden University). |
|
Yuan Y (2014) Natural product chemokine receptor antagonists: what mother nature has offered us?. Current topics in medicinal chemistry 14: 1619-1634. |
|
Sima C, E Van Dyke T (2016) Therapeutic targets for management of periodontitis and diabetes. Current pharmaceutical design 22: 2216-2237. |
|
Angela Covino D, Sabbatucci M, Fantuzzi L (2016) The CCL2/CCR2 axis in the pathogenesis of HIV-1 Infection: a new cellular target for therapy?. Current drug targets 17: 76-110. |
|
Desai GS, Desai SV, Gavaskar RS, Mulabagal V, Wu Y, et al. (2015) Blood Glucoseâ€lowering Effect of T. procumbens L.: A Pilot Clinical Study in Individuals with Type 2 Diabetes. Phytotherapy Research 29: 1404-1411. |
|
Charo IF (2013) Blinding the monocytes to protect the heart. Circulation 127: 2006-2008. |
|
Michlmayr D, Lim JK (2014) Chemokine receptors as important regulators of pathogenesis during arboviral encephalitis. |
|
Di Prospero NA, Artis E, Andradeâ€Gordon P, Johnson DL, Vaccaro N, et al. (2014) CCR2 antagonism in patients with type 2 diabetes mellitus: a randomized, placeboâ€controlled study. Diabetes, Obesity and Metabolism 16: 1055-1064. |
|
Barutta F, Bruno G, Grimaldi S, Gruden G (2015) Inflammation in diabetic nephropathy: moving toward clinical biomarkers and targets for treatment. Endocrine 48: 730-742. |
|
Johnson SA, Spurney RF (2015) Twenty years after ACEIs and ARBs: emerging treatment strategies for diabetic nephropathy. American Journal of Physiology-Renal Physiology 309: F807-820. |
|
Solari R, Pease JE, Begg M (2015) Chemokine receptors as therapeutic targets: why aren’t there more drugs?. European journal of pharmacology 746: 363-367. |
|
Kohlgruber A, Lynch L (2015) Adipose tissue inflammation in the pathogenesis of type 2 diabetes. Current diabetes reports 15: 92. |
|
Sullivan TJ, Miao Z, Zhao BN, Ertl LS, Wang Y, et al. (2013) Experimental evidence for the use of CCR2 antagonists in the treatment of type 2 diabetes. Metabolism 62: 1623-1632. |
|
de Zeeuw D, Bekker P, Henkel E, Hasslacher C, Gouni-Berthold I, et al. (2015) The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial. The Lancet Diabetes & Endocrinology 3: 687-696. |
|
Lee SY, Kim SI, Choi ME (2015) Therapeutic targets for treating fibrotic kidney diseases. Translational Research 165: 512-530. |
|
Sullivan T, Miao Z, Dairaghi DJ, Krasinski A, Wang Y, et al. (2013) CCR2 antagonist CCX140-B provides renal and glycemic benefits in diabetic transgenic human CCR2 knockin mice. American Journal of Physiology-Renal Physiology 305: F1288-1297. |
|
Tampe D, Zeisberg M (2014) Potential approaches to reverse or repair renal fibrosis. Nature Reviews Nephrology 10: 226-237. |
|
Esser N, Paquot N, Scheen AJ (2015) Anti-inflammatory agents to treat or prevent type 2 diabetes, metabolic syndrome and cardiovascular disease. Expert opinion on investigational drugs 24: 283-307. |
|
